AIM： To investigate the expression of fragile histidine triad （FHIT） protein, and the possible relationship between FHIT expression and dinicopathological indices in gastric carcinoma. METHODS： FHIT protein expres...AIM： To investigate the expression of fragile histidine triad （FHIT） protein, and the possible relationship between FHIT expression and dinicopathological indices in gastric carcinoma. METHODS： FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis. RESULTS： The FHIT protein expression was positive in 28/76 （36.8%） cases of adenocarcinoma tissue, 22/58 （37.9%） cases of adjacent dysplastic tissue and 76/76 （100%） cases of distal normal gastric mucosa. There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa （P = 0.000）. FHIT protein expression was found in 64.3% （18/28） of grades Ⅰ and Ⅲ cancers, and 20.8% （10/48） of grade Ⅲcancers （P = 0.000）, in 56.3% （18/32） of stages Ⅰ and Ⅱ cancers and 22.7% （10/44） of stages Ⅲ and IV cancers （P = 0.004）, and in 63.6% （14/22） of cancers without metastasis but only 25.9% （14/54） of those with metastasis （P = 0.003）. The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer. Follow-up data showed that there was a significant difference in median survival time between cancer patients with expression of FHIT （71 mo） and those without （33 mo, log rank = 20.78, P = 0.000）. CONCLUSION： FHIT protein is an important tumor suppressor protein. Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma. 2005 The WJG Press and Elsevier Inc. All rights reserved展开更多
Gastric cancer is one of the leading causes of cancerrelated deaths worldwide, although the incidence has gradually decreased in many Western countries. Two main gastric cancer histotypes, intestinal and diffuse, are ...Gastric cancer is one of the leading causes of cancerrelated deaths worldwide, although the incidence has gradually decreased in many Western countries. Two main gastric cancer histotypes, intestinal and diffuse, are recognised. Although most of the described genetic alterations have been observed in both types, different genetic pathways have been hypothesized. Genetic and epigenetic events, including 1q loss of heterozygosity (LOH), microsatellite instability and hypermethylation, have mostly been reported in intestinal-type gastric carcinoma and its precursor lesions, whereas 17p LOH, mutation or loss of E-cadherin are more often implicated in the development of diffuse-type gastric cancer.In this review, we summarize the sometimes contradictory findings regarding those markers which influence the progression of gastric adenocarcinoma.展开更多
文摘目的:探讨DNA修复基因家族成员ERCC1、RRM1和BRCA1在非小细胞肺癌(NSCLC)中的表达及预后意义。方法:应用实时荧光定量PCR技术对32例肺癌及16例癌旁组织中ERCC1、RRM1和BRCA1基因的mRNA进行定量检测。用非参数检验、相关分析、Kap lan-M e ier生存曲线和COX多因素回归分析进行统计分析。结果:NSCLC中ERCC1、RRM1和BRCA1在癌组织内表达量显著高于癌旁组织,且在癌内表达具有正相关性;RRM1在肺鳞癌中高于腺癌,但在不同分期中表达无差异;ERCC1和BRCA1在不同病理类型和分期中表达均无差异;RRM1和BRCA1高表达组的生存期明显长于低表达组;COX多因素回归分析示RRM1表达是影响本组患者预后的独立因素。结论:NSCLC中,ERCC1、RRM1和BRCA1在肺癌组织中的表达显著高于癌旁组织,RRM1和BRCA1高表达组的生存期长于低表达组。RRM1和BRCA1可作为判断预后的一种指标。
文摘AIM： To investigate the expression of fragile histidine triad （FHIT） protein, and the possible relationship between FHIT expression and dinicopathological indices in gastric carcinoma. METHODS： FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis. RESULTS： The FHIT protein expression was positive in 28/76 （36.8%） cases of adenocarcinoma tissue, 22/58 （37.9%） cases of adjacent dysplastic tissue and 76/76 （100%） cases of distal normal gastric mucosa. There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa （P = 0.000）. FHIT protein expression was found in 64.3% （18/28） of grades Ⅰ and Ⅲ cancers, and 20.8% （10/48） of grade Ⅲcancers （P = 0.000）, in 56.3% （18/32） of stages Ⅰ and Ⅱ cancers and 22.7% （10/44） of stages Ⅲ and IV cancers （P = 0.004）, and in 63.6% （14/22） of cancers without metastasis but only 25.9% （14/54） of those with metastasis （P = 0.003）. The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer. Follow-up data showed that there was a significant difference in median survival time between cancer patients with expression of FHIT （71 mo） and those without （33 mo, log rank = 20.78, P = 0.000）. CONCLUSION： FHIT protein is an important tumor suppressor protein. Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma. 2005 The WJG Press and Elsevier Inc. All rights reserved
文摘Gastric cancer is one of the leading causes of cancerrelated deaths worldwide, although the incidence has gradually decreased in many Western countries. Two main gastric cancer histotypes, intestinal and diffuse, are recognised. Although most of the described genetic alterations have been observed in both types, different genetic pathways have been hypothesized. Genetic and epigenetic events, including 1q loss of heterozygosity (LOH), microsatellite instability and hypermethylation, have mostly been reported in intestinal-type gastric carcinoma and its precursor lesions, whereas 17p LOH, mutation or loss of E-cadherin are more often implicated in the development of diffuse-type gastric cancer.In this review, we summarize the sometimes contradictory findings regarding those markers which influence the progression of gastric adenocarcinoma.
